BTAI · BioXcel Therapeutics, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“The Company's history of significant losses, its negative cash flows from operations, its current debt obligations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management's assessment that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Quarterly Report. Although the Company has developed and implemented certain plans, they will not mitigate the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.”